Clinical Trial Update: Phase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating decitabine with TQB2450 or decitabine with anlotinib plus TQB2450 in PD-1 inhibitor–resistant digestive system tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive System Tumors

Drugs mentioned

• Anlotinib (anlotinib)
• Decitabine (Decitabine)
• TQB2450

Snippet

Sponsor: Peking University | Conditions: Patients With Digestive System Tumors Resistant to PD-1 Inhibitors | Phase 1, Phase 2 | Status: UNKNOWN